Teriparatide and Risedronate in the Treatment of Patients with Severe Postmenopausal Osteoporosis: Comparative Effects on Vertebral Fractures.
The purpose of this study is to evaluate if a daily subcutaneous medication is superior in reducing the incidence of new vertebral fractures compared with a weekly oral medication.
October 21, 2013
Rheumatology - Osteoporosis
Christopher Shuhart, MD, MHA
- Must be a postmenopausal woman age 45 or older with vertebral fractures.
- Must be willing to cooperate with the study's schedule of events.